Navigation Links
New Data on the GlycoMark® Test In Patients Taking SGLT-2 Inhibitors To Be Presented at the American Diabetes Association 79th Scientific Sessions
Date:6/4/2019

GlycoMark, Inc. announces new data on the GlycoMark® test in patients on SGLT-2 inhibitors are being presented June 8 – 10 at the American Diabetes Association (ADA) Scientific Sessions 2019 in San Francisco. The GlycoMark test, an FDA-cleared and CE-marked blood test used to monitor glycemic control in patients with diabetes, is uniquely sensitive and specific to detecting high blood glucose levels and glucose variability occurring during the prior 1 to 2 weeks. A low (abnormal) GlycoMark result indicates poor glucose control including postprandial glucose variability, which can be missed in up to 40% of patients with a “good” A1C.(1) The new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors” will be on display in the Clinical Therapeutics/New Technology–SGLT Inhibitors poster sessions Hall F, North, Exhibition Level, June 8 - 10, and attended by GlycoMark Clinical Affairs and study co-author on Sunday, June 9 from 12 - 1 p.m. For interviews or to schedule a meeting with GlycoMark during the ADA Scientific Sessions, please email GlycoMark@L3Healthcare.com.

The GlycoMark Test has not been FDA cleared for monitoring SGLT-2 inhibitor effect. The GlycoMark test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.

Reference: 1. Erlinger TP, Brancati FL. Diabetes Care. 2001 Oct;24(10):1734-8.

About GlycoMark, Inc.

GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region and the Middle East. The GlycoMark test is an FDA-cleared, non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at http://www.GlycoMark.com.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo.

Read the full story at https://www.prweb.com/releases/new_data_on_the_glycomark_test_in_patients_taking_sglt_2_inhibitors_to_be_presented_at_the_american_diabetes_association_79th_scientific_sessions/prweb16353197.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. Glycomark®, Inc. Partners With Shiel Medical Laboratory To Expand Glycomark Test In The Northeast
2. AdventHealth Ocala to Provide Specialized Care to the Youngest Patients on New Pediatric Unit
3. Delta Hospital Employs Telehealth & Remote Patient Monitoring to Extend Care to Rural Patients
4. AdventHealth Delivers on Promise to Keep Patients Safe at Hospitals
5. House Calls May be the Answer for Patients Concerned about Measles and Other Illnesses, says Dr. Michael Farzam of House Call Doctor Los Angeles
6. Patients Today Are Asking - Which Doctors Are on Top?
7. Women's Excellence Interviews Patients on Infertility and Robotic Surgery
8. Dr. Shervin Naderi Awarded the 2019 Patients’ Choice Award
9. Allegheny Health Network Receives $5 Million Federal Grant to Evaluate Enhanced Screening, Intervention in Primary Care Settings for Patients with Substance Use Disorders
10. The LESS Institute and Dr. Kingsley R. Chin Support Patients After Laser Spine Institute Closes
11. Dental Care Alliance Announces New Affiliation Focused on Midland Park, New Jersey’s Youngest Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2019)... , ... June 15, 2019 , ... All families go ... poverty, untreated mental health needs and lack of a support network, they may be ... to remove the children from the home and place them with a relative, familiar ...
(Date:6/14/2019)... ... June 14, 2019 , ... United Breast Cancer Foundation ... for Saturday, July 13th. UBCF is thrilled to return to the “City of ... cancer. This second event was added after an overwhelming response to the Tempur-Pedic® ...
(Date:6/13/2019)... ... June 13, 2019 , ... Endometriosis is a painful, inflammatory disease that occurs when ... , Painful periods , Heavy bleeding , Irregular menstruation , ... , Women’s Excellence uses the latest and newest treatment protocols in dealing with the ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... 30 Second Test (BL30SEC) has been accepted by the 2019 National Conference of ... Appendix N requirements. , The Charm BL30SEC test was validated by third ...
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... Hard money ... just 24 hours and the funds can also be provided quickly. If the documentation ... , Private lenders are able to avoid the federal oversight involved with a traditional ...
Breaking Medicine News(10 mins):
(Date:6/19/2019)... LUIS OBISPO, Calif. (PRWEB) , ... June 19, 2019 , ... ... at the same age and this vitality can be a double-edged sword leading seniors ... Luis Obispo assisted living specialists and Certified Senior Advisors at Elder Placement Professionals ...
(Date:6/19/2019)... ... June 19, 2019 , ... INDIGO ... toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein ... vitro toxicology offerings and allows researchers to perform critical toxicology testing previously available ...
(Date:6/18/2019)... ... June 18, 2019 , ... ... at 11500 W Olympic Blvd Suite 350 Los Angeles, CA, 90064, bringing holistic ... methodologies. , MY Education Guru has created individual programs to assist students ...
Breaking Medicine Technology: